Naltrexone News and Research

RSS

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

Study examines how often adults with opioid use disorder begin and stay on treatment

Opioid use disorder (OUD) medication treatment saves lives, yet fewer than one-third of people with OUD receive evidence-based treatment with medication.

29 Jul 2025

Ketamine's antidepressant effects involve the brain's opioid system

Ketamine is a highly effective, fast-acting antidepressant that works even for patients who have not responded to other medications.

24 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Study highlights the growing toll of parental substance use on American children

A large percentage of American children are growing up in households with at least one parent who uses alcohol or other drugs in problematic ways-raising the risk that those children will go on to do the same, a new study suggests.

13 May 2025

Study reveals low rate of opioid addiction medications after overdose

Medications proven to effectively treat opioid addiction are rarely given after emergency department visits for overdose, and who gets them varies, sometimes greatly, depending on race, ethnicity or geography, University of Michigan researchers say.

12 May 2025

Hospitals can play key role in treating alcohol use disorder

Nearly 30 million adults in the United States experience alcohol use disorder (AUD), but the vast majority of people with this condition do not receive treatment.

21 Apr 2025

Hit hard by opioid crisis, Black patients further hurt by barriers to care

Purple flags, representing the nearly 300 Mecklenburg County residents who died of opioid overdose in 2023, fluttered in the humid breeze last August in recognition of International Overdose Awareness Day on the city’s predominantly Black west side.

2 Apr 2025

Older Americans support insurance coverage for obesity medications

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

27 Mar 2025

Low-dose initiation of buprenorphine for people using fentanyl fails to deliver expected results

During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.

24 Jan 2025

Long-covid patients are frustrated that federal research hasn’t found new treatments

Erica Hayes, 40, has not felt healthy since November 2020 when she first fell ill with covid.

22 Jan 2025

Smartphone app enhances retention and reduces opioid use in patients

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a new study by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) shows.

30 Dec 2024

Anti-obesity medications could help treat alcohol use disorders

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.

4 Dec 2024

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Researchers evaluate changes in alcohol use after initiating antiobesity medication.

29 Nov 2024

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, warranting further clinical investigation.

18 Nov 2024

GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalizations among individuals with alcohol use disorder, AUD.

13 Nov 2024

Study: Medicaid waivers have limited impact on opioid overdose crisis

For generations, the federal government has largely refrained from paying for mental health and substance use treatment in large residential facilities.

4 Nov 2024

Study reveals limited access to opioid treatment in US jails

A new look into addiction treatment availability in the U.S. criminal justice system reveals that fewer than half (43.8%) of 1,028 jails surveyed across the nation offered any form of medication for opioid use disorder, and only 12.8% made these available to anyone with the disorder.

24 Sep 2024

New approach to treat post-COVID symptoms

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

4 Sep 2024

European Society of Cardiology highlights underrecognized link between obesity and heart disease

Obesity is a key factor in cardiovascular disease, prompting the ESC to recommend comprehensive strategies for prevention and management to reduce health risks.

3 Sep 2024